- Home
- PVL vs CRVO Comparison
PVL vs CRVO Comparison
Compare PVL & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- CRVO
- Stock Information
- Founded
- PVL 2011
- CRVO 2001
- Country
- PVL United States
- CRVO United States
- Employees
- PVL N/A
- CRVO N/A
- Industry
- PVL Oil & Gas Production
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- PVL Energy
- CRVO Health Care
- Exchange
- PVL Nasdaq
- CRVO Nasdaq
- Market Cap
- PVL 61.4M
- CRVO 67.4M
- IPO Year
- PVL N/A
- CRVO N/A
- Fundamental
- Price
- PVL $1.83
- CRVO $5.56
- Analyst Decision
- PVL
- CRVO Strong Buy
- Analyst Count
- PVL 0
- CRVO 8
- Target Price
- PVL N/A
- CRVO $25.57
- AVG Volume (30 Days)
- PVL 120.0K
- CRVO 137.9K
- Earning Date
- PVL 01-01-0001
- CRVO 08-08-2025
- Dividend Yield
- PVL 5.14%
- CRVO N/A
- EPS Growth
- PVL N/A
- CRVO N/A
- EPS
- PVL 0.09
- CRVO N/A
- Revenue
- PVL $4,344,009.00
- CRVO $9,308,215.00
- Revenue This Year
- PVL N/A
- CRVO N/A
- Revenue Next Year
- PVL N/A
- CRVO N/A
- P/E Ratio
- PVL $21.75
- CRVO N/A
- Revenue Growth
- PVL N/A
- CRVO 15.14
- 52 Week Low
- PVL $1.04
- CRVO $1.80
- 52 Week High
- PVL $2.00
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- PVL 54.83
- CRVO 30.87
- Support Level
- PVL $1.80
- CRVO $6.31
- Resistance Level
- PVL $1.87
- CRVO $7.20
- Average True Range (ATR)
- PVL 0.08
- CRVO 0.53
- MACD
- PVL -0.01
- CRVO -0.10
- Stochastic Oscillator
- PVL 39.29
- CRVO 0.00
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production the sale of oil and natural gas production from primarily non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.